Lantheus Holdings Inc NASDAQ:LNTH:
LANTHEUS RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR LNTH-2501 (GA 68 EDOTREOTIDE)
LANTHEUS HOLDINGS - FDA CANNOT APPROVE LNTH-2501 NDA BY JUNE 29, 2026 DUE TO MANUFACTURING CONDITIONS
LANTHEUS HOLDINGS - LNTH-2501 NDA APPROVAL REQUIRES RESOLUTION OF FACILITY INSPECTION CONDITIONS
LANTHEUS HOLDINGS - CRL DOES NOT IDENTIFY DATA, SAFETY, OR EFFICACY CONCERNS FOR LNTH-2501